| Literature DB >> 26284518 |
Jinxian Sun1, Jianrong Hu1, Chunlin Tu1, Anyuan Zhong2, Huajun Xu3.
Abstract
BACKGROUND: Epidemiological studies to date have evaluated the association between genetic variants and the susceptibility to obstructive sleep apnea (OSA). However, the results of these studies have been inconclusive. In this current study we performed meta-analysis of genetic association studies (GAS) to pool OSA-susceptible genes in Chinese population, to perform a more precise evaluation of the association.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26284518 PMCID: PMC4540430 DOI: 10.1371/journal.pone.0135942
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of literature search and study selection, with the specification of reasons.
Summary of candidate genes identified from included studies.
| Gene | Chromosome location | Polymorphism | Amino acid change | Cases | Controls |
|---|---|---|---|---|---|
| ACE | 17q23 | I/D | NR | 580 | 438 |
| TNF-α | 6p21.1–21.3 | -308A/G | NR | 864 | 430 |
| IL-6 | 7p21-14 | -572G/C | NR | 451 | 175 |
| 5-HTR2A | 13q14-q21 | -102T/C | NR | 396 | 264 |
| -1438G/A | NR | 489 | 379 | ||
| 5-HTR2C | q24 | -796 C/G | NR | 33 | 28 |
| 5-HTT | 17q11.1–17q12 | LPR | NR | 596 | 756 |
| VNTR | NR | 572 | 708 | ||
| LEPR | 7q31.3 | NR | Gln223Arg | 346 | 339 |
| PPAR-γ | 3p25 | NR | Pro12Ala | 520 | 290 |
| APOE | 19q13.2 | ε2/ε3/ε4 | NR | 436 | 562 |
| ADRB | 5q33.1 | NR | Arg389Gly | 372 | 132 |
| NR | Arg16Gly | 345 | 189 |
Abbreviation: NR, not reported; ACE, angiotensin-converting enzyme; I/D, insertion/deletion; TNF, tumor necrosis factor; IL-6, Interleukin-6; 5-HTR, 5-hydroxytryptamine receptor; 5-HTT, 5-hydroxytryptamine transporter; LPR, linked promoter region; VNTR, variable number tandem repeat; PPAR-γ, peroxisome proliferator-activated receptor; APOE, apolipoprotein E; ADRB, β-adrenergic receptor.
Summary of comparisons of different genetic models for genetic polymorphisms and OSA risk.
| Gene Polymorphism | Effect model | ORG(95%CI) | PQ | I2 | PH | h index |
|---|---|---|---|---|---|---|
| ACE | All model-free | 1.46(0.80–2.66) | 0.00 | 85.1 | 0.18 | 0.91 |
| All allele | 1.62(0.89–2.94) | 0.00 | 89.4 | NC | NC | |
| TNF-α-308G/A | All model-free | 2.01(1.31–3.07) | 0.18 | 36.9 | 0.66 | 0.31 |
| All allele | 2.15(1.39–3.31) | 0.09 | 50.8 | NC | NC | |
| IL-6-572G/C | All model-free | 0.96(0.66–1.40) | 0.24 | 26.9 | NC | 0.70 |
| All allele | 0.99(0.73–1.34) | 0.28 | 15.9 | NC | NC | |
| 5-HT2A -102C/T | All model-free | 1.12(0.86–1.47) | 0.99 | 0 | 0.70 | 0.10 |
| All allele | 0.91(0.73–1.13) | 0.99 | 0 | NC | NC | |
| 5-HT2A-1438G/A | All model-free | 1.63(0.78–3.39) | 0.00 | 93.7 | 0.73 | 0.50 |
| All allele | 2.02(0.83–4.91) | 0.00 | 94.7 | NC | NC | |
| 5-HT2C -796 C/G | All model-free | 1.00(0.37–2.69) | 0.42 | 0 | NC | 5.12 |
| All allele | 0.88(0.35–2.24) | 0.97 | 0 | NC | NC | |
| 5-HTTLPR | All model-free | 1.31(1.09–1.58) | 0.85 | 0 | 0.62 | 0.09 |
| All allele | 1.32(1.12–1.55) | 0.80 | 0 | NC | NC | |
| 5-HTTVNTR | All model-free | 1.85(1.16–2.95) | 0.01 | 55.7 | 0.98 | 0.41 |
| All allele | 1.86(1.12–3.08) | 0.03 | 66.5 | NC | NC | |
| LEPR Gln223Arg | All model-free | 1.09(0.74–1.59) | 0.73 | 0 | 0.45 | -0.62 |
| All allele | 0.91(0.64–1.29) | 0.75 | 0 | NC | NC | |
| PPAR-γ | All model-free | 1.40(0.84–2.31) | 0.80 | 0 | 0.31 | 0.51 |
| All allele | 0.06(0.01–2.66) | 0.00 | 99.2 | NC | NC | |
| APOE | All model-free | 1.79(1.10–2.92) | 0.86 | 0 | NC | NC |
| ADRB1Arg389Gly | All model-free | 0.97(0.67–1.42) | 0.49 | 0 | NC | -0.26 |
| All allele | 0.95(0.68–1.33) | 0.58 | 0 | NC | NC | |
| ADRB2 Arg16Gly | All model-free | 0.93(0.68–1.26) | 0.37 | 0 | NC | NC |
| All allele | 1.11(0.83–1.48) | 0.43 | 0 | NC | 1.24 |
Abbreviation: NC, not calculated; ORG, generalized odds ratio; ACE, angiotensin-converting enzyme; I/D, insertion/deletion; TNF, tumor necrosis factor; IL-6, Interleukin-6; 5-HTR, 5-hydroxytryptamine receptor; 5-HTT, 5-hydroxytryptamine transporter; LPR, linked promoter region; VNTR, variable number tandem repeat; PPAR-γ, peroxisome proliferator-activated receptor; APOE, apolipoprotein E; ADRB, β-adrenergic receptor.